Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis
NCT05162625Phase 2Unknown
- Sponsor
- Universidade Estadual de Campinas
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Moxisurge in endophthalmitis, sponsored by Universidade Estadual de Campinas. Primary endpoint: Incidence of post-traumatic acute endophthalmitis at 45 days. Status: unknown.
02
Drugs
Moxisurge
03
Conditions
endophthalmitis
Beyond the preview
Go deeper on NCT05162625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162625.